Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topical STD/vaginal contraceptive drug studies described in FDA "Points to Consider".

This article was originally published in The Tan Sheet

Executive Summary

TOPICAL STD/VAGINAL CONTRACEPTIVE DRUGS POINTS TO CONSIDER document recommends one-year toxicity studies in non-rodent species to support Phase II/III trials. In addition, six-month rodent studies are suggested for the drugs, which are considered for regulatory purposes to be chronically administered. The full title of FDA's recently-issued document is "Points to Consider in the Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives."





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts